Search results for "PEPTIDE"

showing 10 items of 4589 documents

Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans.

2010

Objectives We aimed to assess whether concurrent administration of atorvastatin would modify the development of tolerance and endothelial dysfunction associated with sustained nitroglycerin (GTN) therapy in humans. Background Animal studies have demonstrated that administration of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors can protect against GTN-induced endothelial dysfunction and tolerance, likely through an antioxidant mechanism. Methods Thirty-six healthy male volunteers were randomized to receive continuous transdermal GTN (0.6 mg/h) and placebo, atorvastatin (80 mg/day) alone, or continuous transdermal GTN (0.6 mg/h) with concurrent atorvastatin (80 mg/day), all for 7 …

AdultMalemedicine.medical_specialtyEndotheliumendotheliumAdolescentBrachial Arterymedicine.medical_treatmentAtorvastatinVasodilator AgentsBlood PressurePlaceboNitroglycerinYoung AdultDouble-Blind MethodHeart RateReference ValuesInternal medicinemedicineAtorvastatinHumansPyrrolesEndothelial dysfunctionSalinetolerancebiologybusiness.industryDrug Administration RoutesDrug Tolerancemedicine.diseaseVasodilationOxidative StressBlood pressuremedicine.anatomical_structureEndocrinologyHeptanoic AcidsCirculatory systemHMG-CoA reductasebiology.proteincardiovascular systemlipids (amino acids peptides and proteins)Endothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusinessmedicine.drugcirculatory and respiratory physiologyJournal of the American College of Cardiology
researchProduct

A multiple biomarker risk score for guiding clinical decisions using a decision curve approach.

2011

Aims: We assessed whether a cardiovascular risk model based on classic risk factors (e.g. cholesterol, blood pressure) could refine disease prediction if it included novel biomarkers (C-reactive protein, N-terminal pro-B-type natriuretic peptide, troponin I) using a decision curve approach which can incorporate clinical consequences. Methods and results: We evaluated whether a model including biomarkers and classic risk factors could improve prediction of 10 year risk of cardiovascular disease (CVD; chronic heart disease and ischaemic stroke) against a classic risk factor model using a decision curve approach in two prospective MORGAM cohorts. This included 7739 men and women with 457 CVD …

AdultMalemedicine.medical_specialtyEpidemiologymedicine.drug_classBlood PressureDiseaseRisk AssessmentDecision Support TechniquesSex FactorsPredictive Value of TestsRisk FactorsInternal medicineTroponin INatriuretic Peptide BrainmedicineNatriuretic peptideHumansRisk thresholdProspective StudiesFramingham Risk Scorebusiness.industryTroponin IAge FactorsMiddle AgedPrognosisPeptide FragmentsSurgeryEuropeBlood pressureC-Reactive ProteinCholesterolCardiovascular DiseasesCohortBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean journal of preventive cardiology
researchProduct

Non-fatal and fatal liver failure associated with valproic acid.

2012

Little is known about hepatotoxicity associated with valproic acid (VPA), a widely used substance in neuropsychiatry.All reported cases to the German Federal Institute for Drugs and Medical Devices between 1993 and 2009 of VPA-induced serious hepatic side effects were evaluated.A total of 132 cases of serious VPA-associated liver failure were identified. Approximately one third (34.8%) occurred under VPA monotherapy, while the majority was seen with VPA plus co-medication, most frequently antiepileptics (34.8%) and benzodiazepines (16.7%). A subgroup of 34 cases (25.8%) had a fatal outcome, the largest number reported to date. Of these, 32.4% were under VPA monotherapy and 67.6% under VPA p…

AdultMalemedicine.medical_specialtyFatal outcomeAdolescentGastroenterologyBenzodiazepinesPharmacovigilancePharmacotherapyInternal medicineGermanyPharmacovigilancemedicineHumansPharmacology (medical)ChildAgedAged 80 and overValproic Acidbusiness.industryValproic AcidLiver failureInfantGeneral MedicineMiddle AgedPsychiatry and Mental healthAnesthesiaConcomitantChild Preschoollipids (amino acids peptides and proteins)AnticonvulsantsDrug Therapy CombinationFemaleChemical and Drug Induced Liver Injurybusinessmedicine.drugPharmacopsychiatry
researchProduct

The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.

2015

Background Cardiovascular disease (CVD) risk is substantially increased in subjects with chronic kidney disease (CKD). The Triglycerides (TG) to High-Density Lipoprotein Cholesterol (HDL-C) ratio is an indirect measure of insulin resistance and an independent predictor of cardiovascular risk. No study to date has been performed to evaluate whether the TG/HDL-C ratio predicts CVD risk in patients with CKD. Methods A total of 197 patients (age 53 ± 12 years) with CKD Stages 1 to 5, were enrolled in this longitudinal, observational, retrospective study. TG/HDL-C ratio, HOMA-IR indexes, serum asymmetric dimethyl arginine (ADMA), high sensitivity C-reactive protein (CRP), parathyroid hormone (PT…

AdultMalemedicine.medical_specialtyFlow mediated dilatationTriglyceride to HDL-cholesterol ratioEndocrinology Diabetes and MetabolismAsymmetric dimethyl arginineClinical BiochemistryRenal functionClinical nutritionArginineGastroenterologychemistry.chemical_compoundEndocrinologyInsulin resistanceHigh-density lipoproteinInternal medicineChronic kidney diseasemedicineHumansLongitudinal StudiesRenal Insufficiency ChronicSerum AlbuminTriglyceridesAgedRetrospective StudiesBiochemistry medicalbiologybusiness.industryCholesterolResearchBiochemistry (medical)C-reactive proteinCholesterol HDLMiddle Agedmedicine.diseaseEndocrinologyC-Reactive ProteinchemistryCardiovascular DiseasesParathyroid Hormonebiology.proteinlipids (amino acids peptides and proteins)FemalebusinessBiomarkersKidney diseaseLipidologyGlomerular Filtration RateLipids in health and disease
researchProduct

Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fast…

2008

Background: Hypertriglyceridemia is a risk factor for cardiovascular disease. Variation in the apolipoprotein A5 (APOA5) and glucokinase regulatory protein (GCKR) genes has been associated with fasting plasma triacylglycerol. Objective: We investigated the combined effects of the GCKR rs780094C→T, APOA5 −1131T→C, and APOA5 56C→G single nucleotide polymorphisms (SNPs) on fasting triacylglycerol in several independent populations and the response to a high-fat meal and fenofibrate interventions. Design: We used a cross-sectional design to investigate the association with fasting triacylglycerol in 8 populations from America, Asia, and Europe (n = 7730 men and women) and 2 intervention studies…

AdultMalemedicine.medical_specialtyGenotypeGene-Nutrient InteractionsMedicine (miscellaneous)Blood lipidsSingle-nucleotide polymorphismPolymorphism Single NucleotideYoung AdultFenofibrateGene FrequencyRisk FactorsInternal medicineHyperlipidemiamedicineHumansGenetic Predisposition to DiseaseApolipoproteins ATriglyceridesAdaptor Proteins Signal TransducingAgedHypolipidemic AgentsHypertriglyceridemiaNutrition and DieteticsFenofibrateGlucokinase regulatory proteinbiologyGlucokinaseHypertriglyceridemianutritional and metabolic diseasesGenetic VariationFastingMiddle Agedmedicine.diseasePostprandial PeriodDietary FatsPostprandialEndocrinologyCross-Sectional StudiesTreatment OutcomeApolipoprotein A-Vbiology.proteinlipids (amino acids peptides and proteins)Femalemedicine.drugThe American journal of clinical nutrition
researchProduct

Adrenomedullin and arterial stiffness: integrative approach combining monocyte ADM expression, plasma MR-Pro-ADM, and genome-wide association study.

2014

Background— Adrenomedullin (ADM) is a circulating vasoactive peptide involved in vascular homeostasis and endothelial function. Single nucleotide polymorphisms of the ADM gene are associated with blood pressure variability, and elevated levels of plasma midregional proadrenomedullin (MR-pro-ADM) are associated with cardiovascular diseases. Methods and Results— We investigated the sources of variability of ADM gene expression and plasma MR-pro-ADM concentrations in the general population, and their relationship with markers of atherosclerosis. MR-pro-ADM levels were assessed in 4155 individuals who underwent evaluation of carotid intima-media thickness and arterial rigidity (reflection inde…

AdultMalemedicine.medical_specialtyGenotypeTranscription Geneticmedicine.drug_classPopulationGenome-wide association studySingle-nucleotide polymorphismBiologyCarotid Intima-Media ThicknessPolymorphism Single NucleotideMonocytesArticleCohort Studieschemistry.chemical_compoundAdrenomedullinVascular StiffnessInternal medicineGene expressionGeneticsmedicineNatriuretic peptideHumansProtein PrecursorseducationGenetics (clinical)AgedCreatinineeducation.field_of_studyGene Expression ProfilingGenetic VariationMiddle Agedmedicine.diseaseAtherosclerosisAdrenomedullinEndocrinologyCarotid ArterieschemistryGene Expression RegulationArterial stiffnessLinear ModelsFemaleCardiology and Cardiovascular MedicineTranscriptomeGenome-Wide Association StudyCirculation. Cardiovascular genetics
researchProduct

The effects of amino acid supplementation on hormonal responses to resistance training overreaching.

2005

The purpose of this investigation was to examine the effects of amino acid supplementation on muscular performance and resting hormone concentrations during resistance training overreaching. Seventeen resistance-trained men were randomly assigned to either an amino acid (AA) or a placebo (P) group and underwent 4 weeks of total-body resistance training designed to induce a state of overreaching. The protocol consisted of two 2-week phases (phase 1, 3 sets of 8 exercises performed for 8-12 repetitions; phase 2, 5 sets of 5 exercises performed for 3-5 repetitions). Muscle strength and resting blood samples were determined before (T1) and at the end of each training week (T2-T5). One-repetitio…

AdultMalemedicine.medical_specialtyGlobulinAnabolismHydrocortisoneEndocrinology Diabetes and MetabolismBench presschemistry.chemical_compoundHemoglobinsEndocrinologyDouble-Blind MethodInternal medicineSex Hormone-Binding GlobulinmedicineHumansTestosteroneAmino AcidsInsulin-Like Growth Factor ICreatine KinaseTestosteroneExercise TolerancebiologyHuman Growth HormoneOverreachingHormonesPeptide FragmentsUric AcidEndocrinologychemistryDietary Supplementsbiology.proteinUric acidCreatine kinaseHormoneMetabolism: clinical and experimental
researchProduct

Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.

2016

Heart failure (HF) incidence is rising worldwide and HF with preserved ejection fraction (HFpEF) represents nearly half of all cases. Treatment options are still limited in HFpEF in comparison to HF with reduced ejection fraction (HFrEF).We analyzed biomarkers in the general population to characterize HFpEF and HFrEF and defined a biomarker index to differentiate HFpEF from HFrEF. Growth differentiation factor-15 (GDF-15), soluble source of tumorigenicity 2 (sST2), C-reactive protein (CRP) and NT-proBNP were measured in 5000 individuals of the population-based Gutenberg Health Study (GHS). The median follow-up time for all-cause mortality was 7.3years with 213 events.Identification of subje…

AdultMalemedicine.medical_specialtyGrowth Differentiation Factor 15Population030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicineNatriuretic Peptide BrainmedicineHumans030212 general & internal medicineeducationAgedHeart Failureeducation.field_of_studyEjection fractionbiologybusiness.industryIncidence (epidemiology)C-reactive proteinTreatment optionsStroke VolumeMiddle Agedmedicine.diseasePrognosisInterleukin-1 Receptor-Like 1 ProteinPeptide FragmentsC-Reactive ProteinHeart failurebiology.proteinCardiologyBiomarker (medicine)FemaleGDF15Cardiology and Cardiovascular MedicinebusinessBiomarkersInternational journal of cardiology
researchProduct

Plasma levels of atrial natriuretic peptide and hemodynamic function in cardiac disease.

1993

Plasma concentrations of atrial natriuretic peptide were measured in eight patients with cardiac disease but normal resting right atrial pressure, during cardiac catheterization. No patient had clinical evidence of overt heart failure. An increase in peptide concentrations was observed between the aorta or the peripheral vein and the pulmonary artery. A linear relation was found between peripheral vein and pulmonary artery peptide concentration. Mean pulmonary artery and capillary wedge pressure also correlated with the peptide levels. No correlation was observed between mean right atrial pressure and peptide concentration. These findings demonstrate that atrial natriuretic peptide release,…

AdultMalemedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentRadioimmunoassayRenin-Angiotensin SystemCatecholaminesAtrial natriuretic peptideInternal medicinemedicine.arterymedicineHumansPulmonary wedge pressureCardiac catheterizationAgedAged 80 and overAortabusiness.industryLow pressure receptor zonesCentral venous pressureHemodynamicsMiddle Agedmedicine.diseaseArginine VasopressinEndocrinologyHeart failurePulmonary arterycardiovascular systemCardiologyAtrial Function LeftFemaleCardiology and Cardiovascular MedicinebusinessAtrial Natriuretic FactorInternational journal of cardiology
researchProduct

Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders

2004

Mutations in ABCA1 have been shown to be the cause of Tangier disease (TD) and some forms of familial hypoalphalipoproteinemia (HA), two genetic disorders characterized by low plasma HDL levels. Here we report six subjects with low HDL, carrying seven ABCA1 mutations, six of which are previously unreported. Two mutations (R557X and H160FsX173) were predicted to generate short truncated proteins; two mutations (E284K and Y482C) were located in the first extracellular loop and two (R1901S and Q2196H) in the C-terminal cytoplasmic domain of ABCA1. Two subjects found to be compound heterozygotes for ABCA1 mutations did not have overt clinical manifestations of TD. Three subjects, all with prema…

AdultMalemedicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaApolipoprotein BAdolescentPremature coronary artery diseaseTangier diseaseCoronary DiseaseBiologyGene mutationmedicine.disease_causeCompound heterozygosityTangier diseaseInternal medicineGenotypeABCA1 genemedicineHumansChildHypoalphalipoproteinemiaSelection BiasAgedApolipoproteins BGeneticsMutationFamilial defective Apo B (FDB)Apolipoprotein A-ICholesterol HDLnutritional and metabolic diseasesMiddle Agedmedicine.diseaseLipoprotein lipaseTangier disease; Familial HDL deficiency; ABCA1 gene; Familial defective Apo B (FDB); Lipoprotein lipase; Premature coronary artery diseaseEndocrinologyChild PreschoolMutationbiology.proteinlipids (amino acids peptides and proteins)Allelic heterogeneityATP-Binding Cassette TransportersFemaleCardiology and Cardiovascular MedicineFamilial HDL deficiencyATP Binding Cassette Transporter 1
researchProduct